CN1478495A - Chinese Medicinal composition for anticancer and its preparation method - Google Patents
Chinese Medicinal composition for anticancer and its preparation method Download PDFInfo
- Publication number
- CN1478495A CN1478495A CNA021295131A CN02129513A CN1478495A CN 1478495 A CN1478495 A CN 1478495A CN A021295131 A CNA021295131 A CN A021295131A CN 02129513 A CN02129513 A CN 02129513A CN 1478495 A CN1478495 A CN 1478495A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- fructus
- radix
- rhizoma
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
An anticancer Chinese medicine is prepared from 20 Chinese-medicinal materials including honeysuckle flower, astragalus root, red sage root, haw, etc through pulverizing part of them, decocting others, mixing, and granulating. Its advantage is high curative effect.
Description
Invention field
The invention discloses a kind of Chinese medicine pharmaceutical composition and preparation method thereof, particularly relate to a kind of Chinese medicine pharmaceutical composition and preparation method thereof with antitumaous effect.
Background technology
Now, the treatment of malignant tumor is still based on traditional operation, radiotherapy, three kinds of mode treatments of chemotherapy.Yet malignant tumor is early stage, often lacks specific symptom, after diagnosing middles and advanced stage that belong to more, often lost the surgical engine meeting, because the whole body situation is poor, also hard to bear strong radiotherapy, the chemotherapy etc. of being subjected to, or because chemotherapy repeatedly, tumor cell produces drug resistance, and conventional chemotherapy difficulty again proves effective.It is long-pending that motherland's medical science thinks that cancer belongs to disease, how because of the pent-up of feelings will, and the diet internal injury, positive QI-insufficiency, evil malicious internal resistance, stagnation of QI-blood, due to the bright sun imbalance such as internal organs are deficient, Chinese medicine has become one of main treatment means.Seek determined curative effect, the PTS of safety non-toxic is current tumor research focus, is also looked forward to by numerous tumor patients.
Summary of the invention
One object of the present invention is to provide a kind of pharmaceutical composition of anti-curing oncoma newly; Another object of the present invention is to provide the method for this pharmaceutical composition of preparation.
The crude drug of pharmaceutical composition of the present invention is formed and proportioning following (by weight):
Flos Lonicerae 1-5 weight portion Radix Astragali 1-3 weight portion Radix Actinidiae Chinensis 1-3 weight portion
Fructus Corni 1-5 weight portion Radix Salviae Miltiorrhizae 0.5-2 weight portion Fructus Crataegi 0.5-2 weight portion
Rhizoma sparganic 1-3 weight portion Spica Prunellae 1-4 weight portion Gekko Swinhonis 0.3-1 weight portion
Rhizoma Curcumae 1-3 weight portion Carapax Trionycis 0.5-3 weight portion Radix Ginseng 1-3 weight portion
Fructus Psoraleae 1-4 weight portion Fructus Akebiae 1-3 weight portion Semen Coicis 1-5 weight portion
Make 1-5 weight portion Rhizoma Smilacis Bockii 1-5 weight portion Radix Et Rhizoma Rhei 0.5-1.5 weight portion June
Rhizoma Zingiberis 1-3 weight portion Fructus Jujubae 1-5 weight portion
The Radix Astragali, Radix Salviae Miltiorrhizae, Semen Coicis, Fructus Akebiae, rhizoma sparganic, Fructus Psoraleae, Radix Ginseng, Fructus Corni, Fructus Crataegi, Rhizoma Curcumae vital energy regualting and blood circulation-promoting, astringency inducing are set upright and are monarch in the side, Spica Prunellae, Gekko Swinhonis, Carapax Trionycis hard masses softening and resolving are minister, make in Flos Lonicerae, Radix Actinidiae Chinensis, June, Rhizoma Smilacis Bockii, Radix Et Rhizoma Rhei detoxification and removing stasis be assistant, Rhizoma Zingiberis, Fructus Jujubae coordinating the actions of various ingredients in a prescription be for making, and plays the temperatureization cold-evil altogether, attacks the effect of tumor toxin expelling.
Medicine of the present invention can also be that crude drug is made by Radix Astragali 1-3 weight portion, Radix Salviae Miltiorrhizae 0.5-2 weight portion, Semen Coicis 1-5 weight portion, Fructus Akebiae 1-3 weight portion, rhizoma sparganic 1-3 weight portion, Fructus Psoraleae 1-4 weight portion, Radix Ginseng 1-3 weight portion, Fructus Corni 1-5 weight portion, Fructus Crataegi 0.5-2 weight portion, Rhizoma Curcumae 1-3 weight portion, Spica Prunellae 1-4 weight portion, Gekko Swinhonis 0.3-1 weight portion, Carapax Trionycis 0.5-3 weight portion.
This preparation of pharmaceutical compositions method:
More than 20 flavor Chinese medicines, get Radix Actinidiae Chinensis, Gekko Swinhonis, Rhizoma Curcumae, Radix Ginseng, Semen Coicis powder and be broken into fine powder, sieve mixing.Make in all the other Flos Loniceraes, the Radix Astragali, Fructus Corni, Radix Salviae Miltiorrhizae, Fructus Crataegi, rhizoma sparganic, Spica Prunellae, Carapax Trionycis, Fructus Psoraleae, Fructus Akebiae, June, Rhizoma Smilacis Bockii, Radix Et Rhizoma Rhei, Rhizoma Zingiberis, Fructus Jujubae decoct with water 2-3 time, merging filtrate, filter, filtrate is condensed into cream, add above-mentioned medicated powder end and adjuvant, mixing is made clinical acceptable forms, as tablet, oral liquid, capsule, granule etc.
Experimental example: in the drug composition oral of the present invention treatment, late malignant tumour patient 198 examples observe
1, ordinary circumstance is originally organized 198 routine tumor patients all from outpatient service and inpatient.Treatment is organized among the 198 routine patients, wherein male 144 examples, women 54 examples, 50 years old (16-84 year) of The median age, matched group 198 examples, wherein male 116 examples, women 82 examples, 51 years old (21-80 year) of The median age.Treatment group primary bronchogenic carcinoma of lung 51 examples, gastric cancer 31 examples, esophageal carcinoma 58 examples, mammary cancer 16 examples, primary hepatocarcinoma 17 examples, cancer of pancreas 5 examples, colonalgia 6 examples, cancer of biliary duct 3 examples, malignant lymphoma 5 examples, osteosarcoma 3 examples, nasopharyngeal carcinoma 3 examples.Matched group gastric cancer 29 examples, esophageal carcinoma 48 examples, primary bronchogenic carcinoma of lung 51 examples, breast carcinoma 20 examples, primary hepatocarcinoma 15 examples, cancer of pancreas 4 examples, colon cancer 1 example, ovarian cancer 6 examples, malignant lymphoma 6 examples, osteosarcoma 4 examples, nasopharynx pain 1 example.The TNM that issues according to International Union Against Cancer of clinical stages is standard and " Chinese kinds of tumor diagnosis and treatment standard " by stages.Treatment group III phases 51 example, IV147 example: control Group II I phases 62 example, IV phases 136 example.Learn by statistics and handle, two groups of clinical datas compare there was no significant difference (P＞0.05), have comparability.
2, the clinical and pathological diagnosis standard in the diagnosis basis common cancer diagnosis and treatment standard of diagnostic criteria primary hepatocarcinoma, all the other malignant tumor all confirm through image and pathological examination.
3, include standard in and meet above-mentioned diagnostic criteria, without excision (except the postoperative recurrence person), or special treatment persons such as radiotherapy, chemotherapy, include this group in and observe the case alternative.
4, exclusion standard (1) severe cardiac hepatic and kidney function obstacle, gastrointestinal tract blocks or borer: (2) KPS behavior state evaluation criteria is scored below 50 minutes, estimates to be less than life cycle 2 months persons; (3) paper tinsel is not stipulated the full person of medication and data.
5, Therapeutic Method is divided into each 198 example of treatment group and matched group according to contrasting homeostatic principle at random, and every example is filled in the observation table.
198 examples are organized in treatment, give this pharmaceutical composition, and every capsules dosage contains crude drug 0.35g, each 4-6 grain, and every day 4 times is oral, and 4 weeks of logotype were 1 course of treatment.
Chemotherapy group 198 examples, digestive system tumor FAM scheme, 5-FU500mgivftt.d3.5.10.12ADM40-50mgivdl MMC6mg.d1.8; Pulmonary carcinoma CAP scheme, CTX600-800mgivdl.8ADM40-50mgivdlDDP40mg ivgtt.D1-3.Be 1 cycle with 21d all, 2 cycles of logotype are 1 course of treatment (other cancerous protuberance conventional chemotherapies).
6, observation index
Curative effect index: (1) clinical symptom remission rate (2) immunology detection (3) X-ray sheet, CT, Mm, four chemical examinations of gastroscopy (4) tumor
7, curative effect determinate standard
According to the objective curative effect determinate standard of WTO solid tumor, promptly alleviate CR fully, part is alleviated PR, no change NC, progress PD, wherein CR+PR is an effective percentage, CR+PR+NC is a tumor body coefficient of stabilization.
8, therapeutic outcome
Short term effect is according to the comparison of imaging examination before and after the treatment, and treatment organizes that CR is 36 examples (18.2%) in 198 examples, and PR is 96 examples (48.5%), NC is 61 examples (30.8%), sun is 5 examples (2.5%), and CR+PR is 132 examples (66.7%), and CR+PR+NC is these 93 examples (97.5%); In chemotherapy group 198 examples, CR is 12 examples (6.1%), and PR is 38 examples (19.2%), and NC is 87 examples (43.9%), and PD is 61 examples (30.8%), and CR+PR is 50 examples (25.3%), and CR+PR+NC is 137 examples (69.2%).Two groups of total remission rates relatively have significant difference (P＜0.01).
Embodiment 1:
Flos Lonicerae 3kg Radix Astragali 2kg Radix Actinidiae Chinensis 2kg Fructus Corni 3kg Radix Salviae Miltiorrhizae 1kg
Fructus Crataegi 1kg rhizoma sparganic 1.5kg Spica Prunellae 2kg Gekko Swinhonis 0.5kg Rhizoma Curcumae 1.5kg
Carapax Trionycis 1kg Radix Ginseng 2kg Fructus Psoraleae 2kg Fructus Akebiae 2kg Semen Coicis 3kg
Make 3kg Rhizoma Smilacis Bockii 3kg Radix Et Rhizoma Rhei 1kg Rhizoma Zingiberis 2kg Fructus Jujubae 3kg June
More than 20 flavor Chinese medicines, get Radix Actinidiae Chinensis, Gekko Swinhonis, Rhizoma Curcumae, Radix Ginseng, Semen Coicis powder and be broken into fine powder, sieve mixing.Make in all the other Flos Loniceraes, the Radix Astragali, Fructus Corni, Radix Salviae Miltiorrhizae, Fructus Crataegi, rhizoma sparganic, Spica Prunellae, Carapax Trionycis, Fructus Psoraleae, Fructus Akebiae, June, Rhizoma Smilacis Bockii, Radix Et Rhizoma Rhei, Rhizoma Zingiberis, Fructus Jujubae decoct with water 2 times, merging filtrate, filter, filtrate is condensed into cream, adds above-mentioned medicated powder end and adjuvant, mixing, use 70% alcohol granulation, drying is made capsule, and every capsules dosage contains suitable crude drug 0.35g.
Embodiment 2:
Radix Astragali 3kg Radix Salviae Miltiorrhizae 2kg Semen Coicis 4kg Fructus Akebiae 3kg
Rhizoma sparganic 3kg Fructus Psoraleae 3kg Radix Ginseng 2kg Fructus Corni 4kg
Fructus Crataegi 2kg Rhizoma Curcumae 1kg Spica Prunellae 3kg Gekko Swinhonis 1kg
Carapax Trionycis 2kg
Make oral liquid according to a conventional method, every 10ml contains suitable crude drug 0.35g.
Claims (8)
1, a kind of pharmaceutical composition of anti-curing oncoma is characterized in that this pharmaceutical composition is made up of following raw material medicaments:
Radix Astragali 1-3 weight portion Radix Salviae Miltiorrhizae 0.5-2 weight portion Semen Coicis 1-5 weight portion
Fructus Akebiae 1-3 weight portion rhizoma sparganic 1-3 weight portion Fructus Psoraleae 1-4 weight portion
Radix Ginseng 1-3 weight portion Fructus Corni 1-5 weight portion Fructus Crataegi 0.5-2 weight portion
Rhizoma Curcumae 1-3 weight portion Spica Prunellae 1-4 weight portion Gekko Swinhonis 0.3-1 weight portion
Carapax Trionycis 0.5-3 weight portion
2, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition is made up of following raw material medicaments: the Radix Astragali 3 weight portions, Radix Salviae Miltiorrhizae 2 weight portions, Semen Coicis 4 weight portions, Fructus Akebiae 3 weight portions, rhizoma sparganic 3 weight portions, Fructus Psoraleae 3 weight portions, Radix Ginseng 2 weight portions, Fructus Corni 4 weight portions, Fructus Crataegi 2 weight portions, Rhizoma Curcumae 1 weight portion, Spica Prunellae 3 weight portions, Gekko Swinhonis 1 weight portion, Carapax Trionycis 2 weight portions.
3, pharmaceutical composition as claimed in claim 1 or 2 is characterized in that this pharmaceutical composition is made up of following raw material medicaments:
Flos Lonicerae 1-5 weight portion Radix Astragali 1-3 weight portion Radix Actinidiae Chinensis 1-3 weight portion
Fructus Corni 1-5 weight portion Radix Salviae Miltiorrhizae 0.5-2 weight portion Fructus Crataegi 0.5-2 weight portion
Rhizoma sparganic 1-3 weight portion Spica Prunellae 1-4 weight portion Gekko Swinhonis 0.3-1 weight portion
Rhizoma Curcumae 1-3 weight portion Carapax Trionycis 0.5-3 weight portion Radix Ginseng 1-3 weight portion
Fructus Psoraleae 1-4 weight portion Fructus Akebiae 1-3 weight portion Semen Coicis 1-5 weight portion
Make 1-5 weight portion Rhizoma Smilacis Bockii 1-5 weight portion Radix Et Rhizoma Rhei 0.5-1.5 weight portion June
Rhizoma Zingiberis 1-3 weight portion Fructus Jujubae 1-5 weight portion
4, pharmaceutical composition as claimed in claim 3 is characterized in that this pharmaceutical composition is made up of following raw material medicaments:
Make 3 weight portions, Rhizoma Smilacis Bockii 3 weight portions, Radix Et Rhizoma Rhei 1 weight portion, Rhizoma Zingiberis 2 weight portions, Fructus Jujubae 3 weight portions in Flos Lonicerae 3 weight portions, the Radix Astragali 2 weight portions, Radix Actinidiae Chinensis 2 weight portions, Fructus Corni 3 weight portions, Radix Salviae Miltiorrhizae 1 weight portion, Fructus Crataegi 1 weight portion, rhizoma sparganic 1.5 weight portions, Spica Prunellae 2 weight portions, Gekko Swinhonis 0.5 weight portion, Rhizoma Curcumae 1.5 weight portions, Carapax Trionycis 1 weight portion, Radix Ginseng 2 weight portions, Fructus Psoraleae 2 weight portions, Fructus Akebiae 2 weight portions, Semen Coicis 3 weight portions, June.
5, preparation of drug combination method as claimed in claim 3 is characterized in that this method is broken into fine powder for getting Radix Actinidiae Chinensis, Gekko Swinhonis, Rhizoma Curcumae, Radix Ginseng, Semen Coicis powder, sieves mixing.Make in all the other Flos Loniceraes, the Radix Astragali, Fructus Corni, Radix Salviae Miltiorrhizae, Fructus Crataegi, rhizoma sparganic, Spica Prunellae, Carapax Trionycis, Fructus Psoraleae, Fructus Akebiae, June, Rhizoma Smilacis Bockii, Radix Et Rhizoma Rhei, Rhizoma Zingiberis, Fructus Jujubae decoct with water 2-3 time, merging filtrate, filter, filtrate is condensed into cream, add above-mentioned medicated powder end and adjuvant, mixing is made clinical acceptable forms.
6, preparation of drug combination method as claimed in claim 4 is characterized in that this method is: get Radix Actinidiae Chinensis, Gekko Swinhonis, Rhizoma Curcumae, Radix Ginseng, Semen Coicis powder and be broken into fine powder, sieve mixing.Make in all the other Flos Loniceraes, the Radix Astragali, Fructus Corni, Radix Salviae Miltiorrhizae, Fructus Crataegi, rhizoma sparganic, Spica Prunellae, Carapax Trionycis, Fructus Psoraleae, Fructus Akebiae, June, Rhizoma Smilacis Bockii, Radix Et Rhizoma Rhei, Rhizoma Zingiberis, Fructus Jujubae decoct with water 2 times, merging filtrate, filter, filtrate is condensed into cream, add above-mentioned medicated powder end and adjuvant, mixing is used 70% alcohol granulation, drying is made capsule.
7, as claim 1, the application of 2 or 4 described pharmaceutical compositions in the preparation anti-tumor drug.
8, the application of pharmaceutical composition as claimed in claim 3 in the preparation anti-tumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021295131A CN1330369C (en) | 2002-08-29 | 2002-08-29 | Chinese Medicinal composition for anticancer and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021295131A CN1330369C (en) | 2002-08-29 | 2002-08-29 | Chinese Medicinal composition for anticancer and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1478495A true CN1478495A (en) | 2004-03-03 |
| CN1330369C CN1330369C (en) | 2007-08-08 |
Family
ID=34144189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021295131A Expired - Fee Related CN1330369C (en) | 2002-08-29 | 2002-08-29 | Chinese Medicinal composition for anticancer and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1330369C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100553662C (en) * | 2006-07-18 | 2009-10-28 | 中国人民解放军第二军医大学 | A kind of antineoplastic Chinese medicine composition and preparation method thereof |
| CN101703713A (en) * | 2009-11-05 | 2010-05-12 | 张文俊 | Chinese medicinal prescription for treating avascular necrosis of femoral head and preparation method thereof |
| CN101700382B (en) * | 2009-11-12 | 2014-12-10 | 张国营 | Cancer pain elimination pill |
| CN105535773A (en) * | 2016-01-25 | 2016-05-04 | 青岛华之草医药科技有限公司 | Method for preparing traditional Chinese medicine composition for treating stomach cancer |
| CN105853973A (en) * | 2016-05-11 | 2016-08-17 | 张士舜 | Traditional Chinese medicinal composition for treating lung adenocarcinoma and preparation method of traditional Chinese medicinal composition |
| CN111991548A (en) * | 2020-09-23 | 2020-11-27 | 王海军 | Anti-tumor traditional Chinese medicine composition and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170556C (en) * | 2000-06-12 | 2004-10-13 | 吴建华 | Chinese medicine for treating neoplasm |
-
2002
- 2002-08-29 CN CNB021295131A patent/CN1330369C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100553662C (en) * | 2006-07-18 | 2009-10-28 | 中国人民解放军第二军医大学 | A kind of antineoplastic Chinese medicine composition and preparation method thereof |
| CN101703713A (en) * | 2009-11-05 | 2010-05-12 | 张文俊 | Chinese medicinal prescription for treating avascular necrosis of femoral head and preparation method thereof |
| CN101703713B (en) * | 2009-11-05 | 2013-04-17 | 张文俊 | Chinese medicinal prescription for treating avascular necrosis of femoral head and preparation method thereof |
| CN101700382B (en) * | 2009-11-12 | 2014-12-10 | 张国营 | Cancer pain elimination pill |
| CN105535773A (en) * | 2016-01-25 | 2016-05-04 | 青岛华之草医药科技有限公司 | Method for preparing traditional Chinese medicine composition for treating stomach cancer |
| CN105853973A (en) * | 2016-05-11 | 2016-08-17 | 张士舜 | Traditional Chinese medicinal composition for treating lung adenocarcinoma and preparation method of traditional Chinese medicinal composition |
| CN111991548A (en) * | 2020-09-23 | 2020-11-27 | 王海军 | Anti-tumor traditional Chinese medicine composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1330369C (en) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100490789C (en) | Enteric coated Chinese medicinal capsule for treating cancer and preparation method thereof | |
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN103386078B (en) | A kind of Chinese medicine composition is preparing the application in treating colon cancer drug | |
| CN111729055A (en) | Preparation method and application of traditional Chinese medicine composition for eliminating dampness and removing toxicity | |
| CN1330369C (en) | Chinese Medicinal composition for anticancer and its preparation method | |
| CN1814158A (en) | Powder for treating stomach-ache and preparing method | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN111729054A (en) | Dampness-resolving toxin-vanquishing traditional Chinese medicine composition, traditional Chinese medicine preparation, preparation method and application thereof | |
| CN1294015A (en) | Medicine for treating thyroid enlargement and thyroidism | |
| CN102028924B (en) | Medicinal composition for late gastric cancer | |
| CN1225258C (en) | Chinese medicine compound preparation for curing pancreatic cancer | |
| CN105535285A (en) | Chinese herbal preparation with antitumor effect and preparation method and application thereof | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN113499415A (en) | Composition for treating cancer and preparation method and application thereof | |
| CN109865123A (en) | A kind of pharmaceutical composition and its preparation method and application for treating recurrent oral ulceration | |
| CN102670831B (en) | Medicinal composition for treating dermatomyositis and preparation method thereof | |
| CN1233416C (en) | Compound pepsin powder for treating child dyspepsia and its preparation method | |
| CN1261156C (en) | Medicine for treating chronic gastroenteritis and colitis | |
| CN100340285C (en) | Medicine for treating gallstone and preparation method thereof | |
| CN1042495C (en) | Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn. | |
| CN1183297A (en) | Katsutoxin pill for tumor and preparing method thereof | |
| CN104689246B (en) | A kind of medicine for the treatment of gastric cancer | |
| CN1065755C (en) | Chinese compound medicine for treatment of hepatic calculus and cholecystitis | |
| CN1064536C (en) | Full-divergence promoting medicine for curing fourth-phase carcinoma of stomach and its processing method | |
| CN118436748A (en) | Traditional Chinese medicine preparation and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070808 Termination date: 20090929 |